Braveheart Bio Inc. (BRVE)
BRVE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BRVE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002131524 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "The Company has evaluated whether there are conditions and events considered in the aggregate that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed financial statements are issued." | 10-Q 2026-11-10 |
| Cash and burn | $121.3M cash; operating cash flow -$12.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 89,870,352 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-08-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $122.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$26.5M | -$24.4M | $121.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q3 2026 2026-06-30 | Not filed | -$15.0M | Not filed | $122.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q3 2026 2026-03-31 | Not filed | -$14.3M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q3 2026 2025-09-30 | Not filed | -$59.1M | -$740K | $67.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q3 2026 2025-06-30 | Not filed | -$381K | Not filed | $2K | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q3 2026 2025-03-31 | Not filed | -$99K | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document S-1/A | 424B4 | 2026-08-06 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 53 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.5% |
| 1 month | +1.5% |
| 3 months | -24.5% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -34.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| STOK | Stoke Therapeutics Inc. | $26.63 | -0.19% | $1.7B |
| AGIO | Agios Pharmaceuticals Inc. | $30.15 | -4.56% | $1.8B |
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| KLRA | Kailera Therapeutics Inc. | $12.57 | -5.28% | $1.6B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier